NEW YORK (GenomeWeb News) — Epigenomics yesterday said it will help Johnson & Johnson unit Centocor identify and analyze cancer-related biomarkers.
 
Under the agreement, Epigenomics will use its Differential Methylation Hybridization microarray to profile samples with the aim selecting patients who are more likely to benefit from one of Centocor’s candidate drugs.
 
Financial terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.